Savara Inc. (SVRA) 10-Year Financial Performance & Capital Metrics

SVRA • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

AboutSavara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.Show more

Revenue $0
EBITDA -$103M -72.0%
Net Income -$96M -75.3%
EPS (Diluted) -0.48 -45.5%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -61.5% -39.5%
ROIC -47.87% -18.1%
Debt/Equity 0.16 -17.4%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 92 (top 8%)

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 20.0% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-39.44%

EPS CAGR

10Y-

5Y-

3Y-

TTM-25.73%

ROCE

10Y Avg-46.37%

5Y Avg-40.31%

3Y Avg-40.89%

Latest-56.53%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	54	400K	0	0	0	257K	0	0	0	0
Revenue Growth %	-0.97%	7406.41%	-1%	-	-	-	-1%	-	-	-
Cost of Goods Sold+	146K	0	363K	526K	38.78M	35.04M	28.99M	27.88M	44.26M	78.03M
COGS % of Revenue	2703.7%	-	-	-	-	136.33%	-	-	-	-
Gross Profit+	-145.95K	400K	-363K	-526K	-38.78M	-34.78M	-28.99M	-27.88M	-44.26M	-78.03M
Gross Margin %	-2702.7%	1%	-	-	-	-135.33%	-	-	-	-
Gross Profit Growth %	-95.28%	3.74%	-1.91%	-0.45%	-72.73%	0.1%	0.17%	0.04%	-0.59%	-0.76%
Operating Expenses+	39.37M	11.35M	29.96M	48.35M	40.24M	14.52M	12.49M	10.96M	15.74M	25.17M
OpEx % of Revenue	729129.63%	28.37%	-	-	-	56.49%	-	-	-	-
Selling, General & Admin	10.96M	2.82M	11.08M	10.65M	12.86M	11.96M	12.35M	10.93M	15.67M	25.04M
SG&A % of Revenue	203018.52%	7.05%	-	-	-	46.55%	-	-	-	-
Research & Development	28.26M	8.18M	18.51M	37.17M	38.78M	35.04M	28.99M	27.88M	44.26M	78.03M
R&D % of Revenue	523407.41%	20.45%	-	-	-	136.33%	-	-	-	-
Other Operating Expenses	4K	-43K	363K	526K	-11.4M	-32.48M	-28.86M	-27.85M	-44.19M	-77.9M
Operating Income+	-39.37M	-10.95M	-29.96M	-70.05M	-79.03M	-49.3M	-41.48M	-38.84M	-60.01M	-103.2M
Operating Margin %	-729129.63%	-27.37%	-	-	-	-191.83%	-	-	-	-
Operating Income Growth %	-0.34%	0.72%	-1.74%	-1.34%	-0.13%	0.38%	0.16%	0.06%	-0.55%	-0.72%
EBITDA+	-39.23M	-10.6M	-29.59M	-69.52M	-78.71M	-49.05M	-41.34M	-38.81M	-59.93M	-103.07M
EBITDA Margin %	-726425.93%	-26.5%	-	-	-	-190.84%	-	-	-	-
EBITDA Growth %	-0.34%	0.73%	-1.79%	-1.35%	-0.13%	0.38%	0.16%	0.06%	-0.54%	-0.72%
D&A (Non-Cash Add-back)	146K	346K	363K	526K	311K	255K	136K	31K	77K	130K
EBIT	-39.24M	-10.83M	-32.27M	-70.03M	-50.74M	-46.11M	-40.63M	-38.04M	-59.21M	-102.4M
Net Interest Income+	-473K	-452K	0	0	-70K	-1.48M	-2.28M	-87.91K	4.44M	6.47M
Interest Income	130K	122K	0	0	0	0	2.28K	88	4.44M	6.47M
Interest Expense	603K	468K	1.16M	11K	70K	1.48M	2.28M	88K	0	0
Other Income/Expense	-469K	-332K	-3.48M	18K	852K	-315K	-1.54M	689K	5.31M	7.32M
Pretax Income+	-39.84M	-11.28M	-33.43M	-70.03M	-78.17M	-49.62M	-43.01M	-38.15M	-54.7M	-95.88M
Pretax Margin %	-737814.81%	-28.2%	-	-	-	-193.05%	-	-	-	-
Income Tax+	0	-357K	-3.63M	-8.51M	0	0	0	0	0	0
Effective Tax Rate %	1%	0.97%	0.89%	0.88%	1%	1%	1%	1%	1%	1%
Net Income+	-39.84M	-10.92M	-29.8M	-61.52M	-78.17M	-49.62M	-43.01M	-38.15M	-54.7M	-95.88M
Net Margin %	-737814.81%	-27.31%	-	-	-	-193.05%	-	-	-	-
Net Income Growth %	-0.39%	0.73%	-1.73%	-1.06%	-0.27%	0.37%	0.13%	0.11%	-0.43%	-0.75%
Net Income (Continuing)	-39.84M	-10.92M	-29.8M	-61.52M	-78.17M	-49.62M	-43.01M	-38.15M	-54.7M	-95.88M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-17.19	-3.27	-1.70	-1.85	-2.62	-0.84	-0.32	-0.25	-0.33	-0.48
EPS Growth %	-0.05%	0.81%	0.48%	-0.09%	-0.42%	0.68%	0.62%	0.22%	-0.32%	-0.45%
EPS (Basic)	-17.19	-3.27	-1.70	-1.85	-2.62	-0.84	-0.32	-0.25	-0.33	-0.48
Diluted Shares Outstanding	2.32M	3.35M	17.52M	33.3M	40.03M	59.31M	133.92M	152.77M	165.2M	198.19M
Basic Shares Outstanding	2.32M	3.35M	17.52M	33.3M	40.03M	59.31M	133.92M	152.77M	165.2M	198.19M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	42.25M	14.61M	97.86M	113.34M	124.07M	85.12M	165M	128.95M	165.95M	202.13M
Cash & Short-Term Investments	40.98M	13.37M	94.31M	110.83M	121.76M	82.19M	161.17M	125.88M	162.32M	196.33M
Cash Only	23.05M	13.37M	22.12M	24.3M	49.8M	22.88M	34.01M	52.1M	26.59M	15.13M
Short-Term Investments	17.93M	0	72.19M	86.53M	71.96M	59.31M	127.16M	73.78M	135.73M	181.2M
Accounts Receivable	0	868K	1.03M	1.68M	1.62M	1.7M	1.14M	954K	1M	1.04M
Days Sales Outstanding	-	792.05	-	-	-	2.41K	-	-	-	-
Inventory	0	337K	2.48M	0	-1.62M	0	-1.14M	2.05M	0	0
Days Inventory Outstanding	-	-	2.49K	-	-	-	-	26.88	-	-
Other Current Assets	1.27M	94K	40K	107K	1.62M	0	1.5M	-1.98M	280K	455K
Total Non-Current Assets+	11.96M	14.32M	61.76M	38.94M	12.14M	12.62M	11.6M	10.82M	11.62M	10.74M
Property, Plant & Equipment	226K	793K	925K	522K	352K	156K	73K	51K	270K	165K
Fixed Asset Turnover	0.00x	0.50x	-	-	-	1.65x	-	-	-	-
Goodwill	3.01M	3.05M	27.08M	26.92M	0	0	0	0	0	0
Intangible Assets	8.55M	10.48M	33.63M	11.37M	11.11M	12.22M	11.27M	10.66M	10.96M	10.34M
Long-Term Investments	-3.4M	-1.13M	-465K	-3.1M	0	0	0	0	0	0
Other Non-Current Assets	183K	131K	131K	131K	673K	250K	251K	116K	387K	242K
Total Assets+	54.22M	28.93M	159.63M	152.29M	136.2M	97.75M	176.6M	139.78M	177.56M	212.88M
Asset Turnover	0.00x	0.01x	-	-	-	0.00x	-	-	-	-
Asset Growth %	-0.23%	-0.47%	4.52%	-0.05%	-0.11%	-0.28%	0.81%	-0.21%	0.27%	0.2%
Total Current Liabilities+	23.17M	3.46M	6.01M	7.25M	10.88M	8.17M	14.66M	5.87M	10.6M	14.72M
Accounts Payable	2.6M	536K	2.78M	3.88M	3.41M	2.6M	1.44M	1.33M	3.5M	4.54M
Days Payables Outstanding	6.5K	-	2.8K	2.69K	32.08	27.03	18.17	17.47	28.9	21.26
Short-Term Debt	10.99M	0	265K	41K	2M	0	8.33M	0	0	0
Deferred Revenue (Current)	1000K	1000K	1000K	250K	0	0	0	0	0	0
Other Current Liabilities	8.15M	47K	1.06M	2.4M	0	1.92M	0	0	4.05M	5.02M
Current Ratio	1.82x	4.23x	16.27x	15.63x	11.40x	10.41x	11.26x	21.98x	15.66x	13.73x
Quick Ratio	1.82x	4.13x	15.86x	15.63x	11.55x	10.41x	11.33x	21.63x	15.66x	13.73x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	7.16M	61.35M	34.3M	36.81M	23.63M	25.19M	17.44M	26.13M	26.59M	26.71M
Long-Term Debt	3.73M	3.45M	14.78M	24.53M	23.11M	25.1M	17.32M	26.08M	26.35M	26.62M
Capital Lease Obligations	25K	579K	297K	0	0	0	0	0	0	0
Deferred Tax Liabilities	3.4M	2.31M	7.18M	3.1M	0	0	0	0	0	0
Other Non-Current Liabilities	0	55.02M	12.05M	12.28M	513K	84K	117K	54K	247K	87K
Total Liabilities	30.33M	64.81M	40.32M	152.29M	34.51M	33.36M	32.1M	32M	37.19M	41.43M
Total Debt+	14.74M	4.47M	15.34M	24.57M	25.55M	25.28M	25.79M	26.14M	26.49M	26.73M
Net Debt	-8.31M	-8.9M	-6.78M	270K	-24.25M	2.4M	-8.22M	-25.96M	-94K	11.61M
Debt / Equity	0.62x	-	0.13x	0.23x	0.25x	0.39x	0.18x	0.24x	0.19x	0.16x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-65.30x	-23.39x	-25.80x	-6367.73x	-1128.93x	-33.27x	-18.18x	-441.35x	-	-
Total Equity+	23.89M	-35.88M	119.31M	108.22M	101.7M	64.38M	144.5M	107.78M	140.37M	171.45M
Equity Growth %	-0.59%	-2.5%	4.33%	-0.09%	-0.06%	-0.37%	1.24%	-0.25%	0.3%	0.22%
Book Value per Share	10.31	-10.72	6.81	3.25	2.54	1.09	1.08	0.71	0.85	0.87
Total Shareholders' Equity	23.89M	-35.88M	119.31M	108.22M	101.7M	64.38M	144.5M	107.78M	140.37M	171.45M
Common Stock	164K	5K	32K	36K	52K	55K	116K	116K	140K	173K
Retained Earnings	-274.97M	-38.41M	-68.2M	-129.72M	-207.89M	-257.51M	-300.52M	-338.67M	-393.37M	-489.25M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-17K	-591K	958K	200K	-17K	942K	5K	-605K	-271K	-750K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-32.95M	-8.37M	-28.23M	-39.27M	-45.12M	-39.84M	-40.08M	-34.55M	-51.06M	-89.09M
Operating CF Margin %	-610166.67%	-20.93%	-	-	-	-155%	-	-	-	-
Operating CF Growth %	-0.34%	0.75%	-2.37%	-0.39%	-0.15%	0.12%	-0.01%	0.14%	-0.48%	-0.74%
Net Income	-39.84M	-10.92M	-29.8M	-61.52M	-78.17M	-49.62M	-43.01M	-38.15M	-54.7M	-95.88M
Depreciation & Amortization	146K	346K	363K	526K	1.01M	693K	367K	167K	77K	130K
Stock-Based Compensation	2.67M	209K	552K	3.74M	4.44M	5.11M	3.26M	2.04M	4.18M	9.86M
Deferred Taxes	6K	-2.41M	-2.82M	-7.06M	25.98M	-219K	1.7M	0	0	0
Other Non-Cash Items	185K	2.91M	5.5M	22.59M	774K	5.9M	449K	428K	-4.69M	-5.03M
Working Capital Changes	3.88M	1.5M	-2.03M	2.45M	847K	-1.71M	-2.85M	960K	4.07M	1.83M
Change in Receivables	961	-7K	-54K	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	1.23M	-1.97M	159K	1.55M	568K	-1.14M	-1.76M	-319K	4.54M	4.2M
Cash from Investing+	3.4M	-8K	-69.11M	-13.62M	15.74M	9.05M	-69.46M	52.65M	-57.12M	-39.94M
Capital Expenditures	-165K	-8K	-495K	-141K	-148K	-3.29M	-57K	-9K	-296K	-25K
CapEx % of Revenue	3055.56%	0.02%	-	-	-	12.82%	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	3.56M	-15.21M	3.44M	10.27M	14.13M	-3.25M	8.2M	0	-56.82K	0
Cash from Financing+	16.8M	5.12M	106.09M	55.19M	54.91M	3.69M	120.81M	87K	82.78M	117.58M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	8.03M	1K	389K	77K	110K	1.91M	-1.35M	2K	0	400K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-33.11M	-8.38M	-28.73M	-39.42M	-45.27M	-43.13M	-40.14M	-34.56M	-51.36M	-89.11M
FCF Margin %	-613222.22%	-20.95%	-	-	-	-167.82%	-	-	-	-
FCF Growth %	-0.34%	0.75%	-2.43%	-0.37%	-0.15%	0.05%	0.07%	0.14%	-0.49%	-0.74%
FCF per Share	-14.29	-2.50	-1.64	-1.18	-1.13	-0.73	-0.30	-0.23	-0.31	-0.45
FCF Conversion (FCF/Net Income)	0.83x	0.77x	0.95x	0.64x	0.58x	0.80x	0.93x	0.91x	0.93x	0.93x
Interest Paid	0	0	0	0	0	0	0	1.61M	0	0
Taxes Paid	2K	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-96.53%	-	-71.43%	-54.07%	-74.48%	-59.75%	-41.19%	-30.24%	-44.08%	-61.5%
Return on Invested Capital (ROIC)	-153.68%	-	-66.33%	-47.54%	-63.75%	-51.27%	-30.64%	-26.71%	-40.53%	-47.87%
Gross Margin	-270270.37%	100%	-	-	-	-13533.46%	-	-	-	-
Net Margin	-73781481.48%	-2730.75%	-	-	-	-19305.45%	-	-	-	-
Debt / Equity	0.62x	-	0.13x	0.23x	0.25x	0.39x	0.18x	0.24x	0.19x	0.16x
Interest Coverage	-65.30x	-23.39x	-25.80x	-6367.73x	-1128.93x	-33.27x	-18.18x	-441.35x	-	-
FCF Conversion	0.83x	0.77x	0.95x	0.64x	0.58x	0.80x	0.93x	0.91x	0.93x	0.93x
Revenue Growth	-96.51%	740640.74%	-100%	-	-	-	-100%	-	-	-

Frequently Asked Questions

Growth & Financials

Savara Inc. (SVRA) grew revenue by 0.0% over the past year. Growth has been modest.

Savara Inc. (SVRA) reported a net loss of $115.6M for fiscal year 2024.

Dividend & Returns

Savara Inc. (SVRA) has a return on equity (ROE) of -61.5%. Negative ROE indicates the company is unprofitable.

Savara Inc. (SVRA) had negative free cash flow of $99.3M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Savara Inc. (SVRA) 10-Year Financial Performance & Capital Metrics

SVRA • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

Revenue $0
EBITDA -$103M -72.0%
Net Income -$96M -75.3%
EPS (Diluted) -0.48 -45.5%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -61.5% -39.5%
ROIC -47.87% -18.1%
Debt/Equity 0.16 -17.4%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 92 (top 8%)

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 20.0% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-39.44%

EPS CAGR

10Y-

5Y-

3Y-

TTM-25.73%

ROCE

10Y Avg-46.37%

5Y Avg-40.31%

3Y Avg-40.89%

Latest-56.53%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	54	400K	0	0	0	257K	0	0	0	0
Revenue Growth %	-0.97%	7406.41%	-1%	-	-	-	-1%	-	-	-
Cost of Goods Sold+	146K	0	363K	526K	38.78M	35.04M	28.99M	27.88M	44.26M	78.03M
COGS % of Revenue	2703.7%	-	-	-	-	136.33%	-	-	-	-
Gross Profit+	-145.95K	400K	-363K	-526K	-38.78M	-34.78M	-28.99M	-27.88M	-44.26M	-78.03M
Gross Margin %	-2702.7%	1%	-	-	-	-135.33%	-	-	-	-
Gross Profit Growth %	-95.28%	3.74%	-1.91%	-0.45%	-72.73%	0.1%	0.17%	0.04%	-0.59%	-0.76%
Operating Expenses+	39.37M	11.35M	29.96M	48.35M	40.24M	14.52M	12.49M	10.96M	15.74M	25.17M
OpEx % of Revenue	729129.63%	28.37%	-	-	-	56.49%	-	-	-	-
Selling, General & Admin	10.96M	2.82M	11.08M	10.65M	12.86M	11.96M	12.35M	10.93M	15.67M	25.04M
SG&A % of Revenue	203018.52%	7.05%	-	-	-	46.55%	-	-	-	-
Research & Development	28.26M	8.18M	18.51M	37.17M	38.78M	35.04M	28.99M	27.88M	44.26M	78.03M
R&D % of Revenue	523407.41%	20.45%	-	-	-	136.33%	-	-	-	-
Other Operating Expenses	4K	-43K	363K	526K	-11.4M	-32.48M	-28.86M	-27.85M	-44.19M	-77.9M
Operating Income+	-39.37M	-10.95M	-29.96M	-70.05M	-79.03M	-49.3M	-41.48M	-38.84M	-60.01M	-103.2M
Operating Margin %	-729129.63%	-27.37%	-	-	-	-191.83%	-	-	-	-
Operating Income Growth %	-0.34%	0.72%	-1.74%	-1.34%	-0.13%	0.38%	0.16%	0.06%	-0.55%	-0.72%
EBITDA+	-39.23M	-10.6M	-29.59M	-69.52M	-78.71M	-49.05M	-41.34M	-38.81M	-59.93M	-103.07M
EBITDA Margin %	-726425.93%	-26.5%	-	-	-	-190.84%	-	-	-	-
EBITDA Growth %	-0.34%	0.73%	-1.79%	-1.35%	-0.13%	0.38%	0.16%	0.06%	-0.54%	-0.72%
D&A (Non-Cash Add-back)	146K	346K	363K	526K	311K	255K	136K	31K	77K	130K
EBIT	-39.24M	-10.83M	-32.27M	-70.03M	-50.74M	-46.11M	-40.63M	-38.04M	-59.21M	-102.4M
Net Interest Income+	-473K	-452K	0	0	-70K	-1.48M	-2.28M	-87.91K	4.44M	6.47M
Interest Income	130K	122K	0	0	0	0	2.28K	88	4.44M	6.47M
Interest Expense	603K	468K	1.16M	11K	70K	1.48M	2.28M	88K	0	0
Other Income/Expense	-469K	-332K	-3.48M	18K	852K	-315K	-1.54M	689K	5.31M	7.32M
Pretax Income+	-39.84M	-11.28M	-33.43M	-70.03M	-78.17M	-49.62M	-43.01M	-38.15M	-54.7M	-95.88M
Pretax Margin %	-737814.81%	-28.2%	-	-	-	-193.05%	-	-	-	-
Income Tax+	0	-357K	-3.63M	-8.51M	0	0	0	0	0	0
Effective Tax Rate %	1%	0.97%	0.89%	0.88%	1%	1%	1%	1%	1%	1%
Net Income+	-39.84M	-10.92M	-29.8M	-61.52M	-78.17M	-49.62M	-43.01M	-38.15M	-54.7M	-95.88M
Net Margin %	-737814.81%	-27.31%	-	-	-	-193.05%	-	-	-	-
Net Income Growth %	-0.39%	0.73%	-1.73%	-1.06%	-0.27%	0.37%	0.13%	0.11%	-0.43%	-0.75%
Net Income (Continuing)	-39.84M	-10.92M	-29.8M	-61.52M	-78.17M	-49.62M	-43.01M	-38.15M	-54.7M	-95.88M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-17.19	-3.27	-1.70	-1.85	-2.62	-0.84	-0.32	-0.25	-0.33	-0.48
EPS Growth %	-0.05%	0.81%	0.48%	-0.09%	-0.42%	0.68%	0.62%	0.22%	-0.32%	-0.45%
EPS (Basic)	-17.19	-3.27	-1.70	-1.85	-2.62	-0.84	-0.32	-0.25	-0.33	-0.48
Diluted Shares Outstanding	2.32M	3.35M	17.52M	33.3M	40.03M	59.31M	133.92M	152.77M	165.2M	198.19M
Basic Shares Outstanding	2.32M	3.35M	17.52M	33.3M	40.03M	59.31M	133.92M	152.77M	165.2M	198.19M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	42.25M	14.61M	97.86M	113.34M	124.07M	85.12M	165M	128.95M	165.95M	202.13M
Cash & Short-Term Investments	40.98M	13.37M	94.31M	110.83M	121.76M	82.19M	161.17M	125.88M	162.32M	196.33M
Cash Only	23.05M	13.37M	22.12M	24.3M	49.8M	22.88M	34.01M	52.1M	26.59M	15.13M
Short-Term Investments	17.93M	0	72.19M	86.53M	71.96M	59.31M	127.16M	73.78M	135.73M	181.2M
Accounts Receivable	0	868K	1.03M	1.68M	1.62M	1.7M	1.14M	954K	1M	1.04M
Days Sales Outstanding	-	792.05	-	-	-	2.41K	-	-	-	-
Inventory	0	337K	2.48M	0	-1.62M	0	-1.14M	2.05M	0	0
Days Inventory Outstanding	-	-	2.49K	-	-	-	-	26.88	-	-
Other Current Assets	1.27M	94K	40K	107K	1.62M	0	1.5M	-1.98M	280K	455K
Total Non-Current Assets+	11.96M	14.32M	61.76M	38.94M	12.14M	12.62M	11.6M	10.82M	11.62M	10.74M
Property, Plant & Equipment	226K	793K	925K	522K	352K	156K	73K	51K	270K	165K
Fixed Asset Turnover	0.00x	0.50x	-	-	-	1.65x	-	-	-	-
Goodwill	3.01M	3.05M	27.08M	26.92M	0	0	0	0	0	0
Intangible Assets	8.55M	10.48M	33.63M	11.37M	11.11M	12.22M	11.27M	10.66M	10.96M	10.34M
Long-Term Investments	-3.4M	-1.13M	-465K	-3.1M	0	0	0	0	0	0
Other Non-Current Assets	183K	131K	131K	131K	673K	250K	251K	116K	387K	242K
Total Assets+	54.22M	28.93M	159.63M	152.29M	136.2M	97.75M	176.6M	139.78M	177.56M	212.88M
Asset Turnover	0.00x	0.01x	-	-	-	0.00x	-	-	-	-
Asset Growth %	-0.23%	-0.47%	4.52%	-0.05%	-0.11%	-0.28%	0.81%	-0.21%	0.27%	0.2%
Total Current Liabilities+	23.17M	3.46M	6.01M	7.25M	10.88M	8.17M	14.66M	5.87M	10.6M	14.72M
Accounts Payable	2.6M	536K	2.78M	3.88M	3.41M	2.6M	1.44M	1.33M	3.5M	4.54M
Days Payables Outstanding	6.5K	-	2.8K	2.69K	32.08	27.03	18.17	17.47	28.9	21.26
Short-Term Debt	10.99M	0	265K	41K	2M	0	8.33M	0	0	0
Deferred Revenue (Current)	1000K	1000K	1000K	250K	0	0	0	0	0	0
Other Current Liabilities	8.15M	47K	1.06M	2.4M	0	1.92M	0	0	4.05M	5.02M
Current Ratio	1.82x	4.23x	16.27x	15.63x	11.40x	10.41x	11.26x	21.98x	15.66x	13.73x
Quick Ratio	1.82x	4.13x	15.86x	15.63x	11.55x	10.41x	11.33x	21.63x	15.66x	13.73x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	7.16M	61.35M	34.3M	36.81M	23.63M	25.19M	17.44M	26.13M	26.59M	26.71M
Long-Term Debt	3.73M	3.45M	14.78M	24.53M	23.11M	25.1M	17.32M	26.08M	26.35M	26.62M
Capital Lease Obligations	25K	579K	297K	0	0	0	0	0	0	0
Deferred Tax Liabilities	3.4M	2.31M	7.18M	3.1M	0	0	0	0	0	0
Other Non-Current Liabilities	0	55.02M	12.05M	12.28M	513K	84K	117K	54K	247K	87K
Total Liabilities	30.33M	64.81M	40.32M	152.29M	34.51M	33.36M	32.1M	32M	37.19M	41.43M
Total Debt+	14.74M	4.47M	15.34M	24.57M	25.55M	25.28M	25.79M	26.14M	26.49M	26.73M
Net Debt	-8.31M	-8.9M	-6.78M	270K	-24.25M	2.4M	-8.22M	-25.96M	-94K	11.61M
Debt / Equity	0.62x	-	0.13x	0.23x	0.25x	0.39x	0.18x	0.24x	0.19x	0.16x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-65.30x	-23.39x	-25.80x	-6367.73x	-1128.93x	-33.27x	-18.18x	-441.35x	-	-
Total Equity+	23.89M	-35.88M	119.31M	108.22M	101.7M	64.38M	144.5M	107.78M	140.37M	171.45M
Equity Growth %	-0.59%	-2.5%	4.33%	-0.09%	-0.06%	-0.37%	1.24%	-0.25%	0.3%	0.22%
Book Value per Share	10.31	-10.72	6.81	3.25	2.54	1.09	1.08	0.71	0.85	0.87
Total Shareholders' Equity	23.89M	-35.88M	119.31M	108.22M	101.7M	64.38M	144.5M	107.78M	140.37M	171.45M
Common Stock	164K	5K	32K	36K	52K	55K	116K	116K	140K	173K
Retained Earnings	-274.97M	-38.41M	-68.2M	-129.72M	-207.89M	-257.51M	-300.52M	-338.67M	-393.37M	-489.25M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-17K	-591K	958K	200K	-17K	942K	5K	-605K	-271K	-750K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-32.95M	-8.37M	-28.23M	-39.27M	-45.12M	-39.84M	-40.08M	-34.55M	-51.06M	-89.09M
Operating CF Margin %	-610166.67%	-20.93%	-	-	-	-155%	-	-	-	-
Operating CF Growth %	-0.34%	0.75%	-2.37%	-0.39%	-0.15%	0.12%	-0.01%	0.14%	-0.48%	-0.74%
Net Income	-39.84M	-10.92M	-29.8M	-61.52M	-78.17M	-49.62M	-43.01M	-38.15M	-54.7M	-95.88M
Depreciation & Amortization	146K	346K	363K	526K	1.01M	693K	367K	167K	77K	130K
Stock-Based Compensation	2.67M	209K	552K	3.74M	4.44M	5.11M	3.26M	2.04M	4.18M	9.86M
Deferred Taxes	6K	-2.41M	-2.82M	-7.06M	25.98M	-219K	1.7M	0	0	0
Other Non-Cash Items	185K	2.91M	5.5M	22.59M	774K	5.9M	449K	428K	-4.69M	-5.03M
Working Capital Changes	3.88M	1.5M	-2.03M	2.45M	847K	-1.71M	-2.85M	960K	4.07M	1.83M
Change in Receivables	961	-7K	-54K	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	1.23M	-1.97M	159K	1.55M	568K	-1.14M	-1.76M	-319K	4.54M	4.2M
Cash from Investing+	3.4M	-8K	-69.11M	-13.62M	15.74M	9.05M	-69.46M	52.65M	-57.12M	-39.94M
Capital Expenditures	-165K	-8K	-495K	-141K	-148K	-3.29M	-57K	-9K	-296K	-25K
CapEx % of Revenue	3055.56%	0.02%	-	-	-	12.82%	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	3.56M	-15.21M	3.44M	10.27M	14.13M	-3.25M	8.2M	0	-56.82K	0
Cash from Financing+	16.8M	5.12M	106.09M	55.19M	54.91M	3.69M	120.81M	87K	82.78M	117.58M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	8.03M	1K	389K	77K	110K	1.91M	-1.35M	2K	0	400K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-33.11M	-8.38M	-28.73M	-39.42M	-45.27M	-43.13M	-40.14M	-34.56M	-51.36M	-89.11M
FCF Margin %	-613222.22%	-20.95%	-	-	-	-167.82%	-	-	-	-
FCF Growth %	-0.34%	0.75%	-2.43%	-0.37%	-0.15%	0.05%	0.07%	0.14%	-0.49%	-0.74%
FCF per Share	-14.29	-2.50	-1.64	-1.18	-1.13	-0.73	-0.30	-0.23	-0.31	-0.45
FCF Conversion (FCF/Net Income)	0.83x	0.77x	0.95x	0.64x	0.58x	0.80x	0.93x	0.91x	0.93x	0.93x
Interest Paid	0	0	0	0	0	0	0	1.61M	0	0
Taxes Paid	2K	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-96.53%	-	-71.43%	-54.07%	-74.48%	-59.75%	-41.19%	-30.24%	-44.08%	-61.5%
Return on Invested Capital (ROIC)	-153.68%	-	-66.33%	-47.54%	-63.75%	-51.27%	-30.64%	-26.71%	-40.53%	-47.87%
Gross Margin	-270270.37%	100%	-	-	-	-13533.46%	-	-	-	-
Net Margin	-73781481.48%	-2730.75%	-	-	-	-19305.45%	-	-	-	-
Debt / Equity	0.62x	-	0.13x	0.23x	0.25x	0.39x	0.18x	0.24x	0.19x	0.16x
Interest Coverage	-65.30x	-23.39x	-25.80x	-6367.73x	-1128.93x	-33.27x	-18.18x	-441.35x	-	-
FCF Conversion	0.83x	0.77x	0.95x	0.64x	0.58x	0.80x	0.93x	0.91x	0.93x	0.93x
Revenue Growth	-96.51%	740640.74%	-100%	-	-	-	-100%	-	-	-

Frequently Asked Questions

Growth & Financials

Savara Inc. (SVRA) grew revenue by 0.0% over the past year. Growth has been modest.

Savara Inc. (SVRA) reported a net loss of $115.6M for fiscal year 2024.

Dividend & Returns

Savara Inc. (SVRA) has a return on equity (ROE) of -61.5%. Negative ROE indicates the company is unprofitable.

Savara Inc. (SVRA) had negative free cash flow of $99.3M in fiscal year 2024, likely due to heavy capital investments.